A significant advancement in the battle against Alzheimer's disease has been made in Italy. According to the findings of a randomized clinical trial, Transcranial Magnetic Stimulation (TMS) can dramatically reduce disease development in people with mild to moderate Alzheimer's disease. This was declared by the University of Rome Tor Vergata. The study, the first of its type to assess the effects of long-term treatment for 52 weeks, found that patients who received TMS reported a 52% reduction in disease progression compared to the placebo group. Cognitive functions, daily autonomy, and behavioral disorder management all showed improvements. TMS is a harmless and non-invasive method that employs brief, intense magnetic pulses to stimulate specific brain regions. In this study, the researchers employed a repetitive form of stimulation (rTMS) to target the precuneus, a brain region that has been previously identified as critical in Alzheimer's disease. The trial was conducted at the Santa Lucia IRCCS Foundation by the team of Professor Giacomo Koch, a professor of Physiology at the University of Ferrara, with the assistance of the Ministry of Health, the Ministry of University and Research, and the BrightFocus Foundation.